Holen Sie sich die Stockscreener-App
3.6822
2.07%
-0.0778
Collplant Biotechnologies Ltd Aktie (CLGN) Neueste Nachrichten
Collplant stock hits 52-week low at $3.75 amid market challenges - Investing.com
EF Hutton Initiates Coverage of CollPlant Biotechnologies (CLGN) with Buy Recommendation - MSN
Collplant stock hits 52-week low at $4.05 amid market challenges - Investing.com India
Collplant stock hits 52-week low at $4.05 amid market challenges By Investing.com - Investing.com South Africa
CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Short Interest Update - Defense World
CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Short Interest Up 5.3% in September - MarketBeat
Benjamin F. Edwards & Company Inc. Sells 10,690 Shares of CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) - Defense World
CollPlant Shareholders Approve Key Proposals - TipRanks
CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Sees Large Growth in Short Interest - MarketBeat
CollPlant (CLGN), Stratasys Initiate Study for Breast Implants - MSN
CollPlant and Stratasys Launch Pre-clinical Trial for Regenerative 3D-Printed Breast Implants - 3DPrint.com
The Stratasys’ Origin® printer to be tested for CollPlant’s 3D-printed breast implants - 3d adept media
HC Wainwright Weighs in on CollPlant Biotechnologies Ltd.'s Q3 2024 Earnings (NASDAQ:CLGN) - MarketBeat
Head-To-Head Analysis: Envoy Medical (NASDAQ:COCH) and CollPlant Biotechnologies (NASDAQ:CLGN) - Defense World
HC Wainwright Weighs in on CollPlant Biotechnologies Ltd.’s Q3 2024 Earnings (NASDAQ:CLGN) - Defense World
FY2027 EPS Estimates for CollPlant Biotechnologies Ltd. Reduced by HC Wainwright (NASDAQ:CLGN) - MarketBeat
HC Wainwright Research Analysts Cut Earnings Estimates for CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) - Defense World
Global Tooth Regeneration Market Size To Worth USD 8.20 Billion By 2033 | CAGR Of 6.18% - GlobeNewswire Inc.
CollPlant Schedules Shareholder Meeting - Investing.com India
CollPlant Schedules Shareholder Meeting By Investing.com - Investing.com Australia
Cracking The Code: Understanding Analyst Reviews For CollPlant Biotechnologies - Benzinga
CollPlant Biotechnologies’ (CLGN) Buy Rating Reaffirmed at HC Wainwright - Defense World
CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Q2 2024 Earnings Call Transcript - Insider Monkey
Earnings call: CollPlant Biotechnologies reports Q2 2024 financials By Investing.com - Investing.com Australia
CollPlant Biotechnologies Ltd (CLGN) Q2 2024 Earnings Call Trans - GuruFocus.com
Q2 2024 Collplant Biotechnologies Ltd Earnings Call Transcript - GuruFocus.com
CollPlant Announces Upcoming Shareholder Meeting - TipRanks
Collplant stock hits 52-week low at $4.1 amid market challenges - Investing.com
Even after rising 10% this past week, CollPlant Biotechnologies (NASDAQ:CLGN) shareholders are still down 71% over the past three years - Yahoo Finance
COLLPLANT BIOTECHNOLOGIES REPORTS 2024 SECOND QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE - Nasdaq
We're Interested To See How CollPlant Biotechnologies (NASDAQ:CLGN) Uses Its Cash Hoard To Grow - Simply Wall St
CollPlant and Stratasys launch pre-clinical study for 3D implants - Investing.com India
CollPlant Biotechnologies (FRA:CPT) Earnings per Share (Dil - GuruFocus.com
CollPlant Biotechnologies (FRA:CPT) Cash Flow for Lease Fin - GuruFocus.com
CollPlant Biotechnologies (FRA:CPT) Market Cap : €48.54 Mil (As of Aug. 19, 2024) - GuruFocus.com
CollPlant and Stratasys announce pre-clinical study for regenerative breast implants - Med-Tech Innovation
Stratasys and CollPlant commence pre-clinical study for 3D printed regenerative breast implants - TCT Magazine
CollPlant and Stratasys Announce Pre-clinical Study for Regenerative Commercial-Sized Breast Implants - Lelezard
CollPlant Biotechnologies (FRA:CPT) Cash Flow from Financin - GuruFocus.com
CollPlant Biotechnologies (FRA:CPT) Cash-to-Debt : 7.69 (As of Mar. 2024) - GuruFocus.com
CollPlant Biotechnologies (FRA:CPT) Machinery, Furniture, E - GuruFocus.com
CLGN (CollPlant Biotechnologies) Debt-to-Revenue : 7.70 (As of Mar. 2024) - GuruFocus.com
CLGN (CollPlant Biotechnologies) EV-to-Revenue : 3.11 (As of Aug. 18, 2024) - GuruFocus.com
CLGN (CollPlant Biotechnologies) 14-Day RSI : 48.58 (As of Aug. 18, 2024) - GuruFocus.com
CollPlant Biotechnologies (FRA:CPT) Long-Term Debt & Capita - GuruFocus.com
CollPlant Biotechnologies (FRA:CPT) Earnings Yield % : N/A% (As of Aug. 17, 2024) - GuruFocus.com
CollPlant Biotechnologies (FRA:CPT) Accounts Receivable : €0.08 Mil (As of Mar. 2024) - GuruFocus.com
CollPlant Biotechnologies (FRA:CPT) Change In Receivables : €0.34 Mil (TTM As of Mar. 2024) - GuruFocus.com
CollPlant Biotechnologies (FRA:CPT) Inventory Turnover : 0.80 (As of Mar. 2024) - GuruFocus.com
CollPlant Biotechnologies (FRA:CPT) Free Cash Flow per Shar - GuruFocus.com
CollPlant Biotechnologies (FRA:CPT) Preferred Stock : €0.00 Mil (As of Mar. 2024) - GuruFocus.com
CLGN (CollPlant Biotechnologies) Long-Term Debt & Capital L - GuruFocus.com
CollPlant Biotechnologies (FRA:CPT) Operating Cash Flow per Share : €-0.19 (TTM As of Mar. 2024) - GuruFocus.com
CollPlant Biotechnologies (FRA:CPT) Dividends per Share : €0.00 (TTM As of Mar. 2024) - GuruFocus.com
1.11%
0.26%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):